• HSD82 Prisoners’ Preferences for Virtual Care Design and Delivery in the Correctional Setting: A Discrete Choice Experiment

    Jul 1, 2025, 00:00

  • EE499 Costs of Type 2 Diabetes Mellitus and Obesity in Colombian Caribbean Poor Population: A Top-Down Approach from a Cardiovascular Risk Cohort, 2020-2022

    Jul 1, 2025, 00:00

  • EPH102 Changes in the Prevalence of Diabetes Mellitus in Pregnancy : A Nationwide Analysis From Hungary

    Jul 1, 2025, 00:00

  • EE344 Evaluating the Budget Impact of an Intrauterine Device for Postpartum Hemorrhage Management: A Hospital Perspective

    Jul 1, 2025, 00:00

  • MSR69 Emerging Trends in AI Applications: Shaping Pharmacoepidemiology and Health Technology Assessments

    Jul 1, 2025, 00:00

  • PCR5 Perspectives of Adult Patients and Caregivers on the Management and Challenges Associated With Neurofibromatosis Type 1 and Plexiform Neurofibroma: A Multinational, Qualitative Study

    Jul 1, 2025, 00:00

  • MSR19 An Open-Source LLM Framework For Transparent Data Extraction From Research Papers

    Jul 1, 2025, 00:00

  • HPR92 Evolution of Technology Diffusion within Brazilian Universal Healthcare System (Sistema Único de Saúde - SUS) 2+ Years After Listing of Antiangiogenics Treatment for Age-Related Macular Edema (AMD)

    Jul 1, 2025, 00:00

  • EPH56 Real-World Demographics and Clinical Characteristics of Multiple Myeloma Patients in a Colombian HMO During 2015-2023

    Jul 1, 2025, 00:00

  • RWD66 Utilizing Generative AI to Automate Model Selection and Network Meta-Analyses

    Jul 1, 2025, 00:00

  • EE272 Healthcare Resource Utilization in Patients with Type 1 Diabetes with or without Prior Type 2 Diabetes Misdiagnosis: A Study in a U.S. Managed Care Population

    Jul 1, 2025, 00:00

  • MSR42 Three Different Methods to Estimate a Rare Disease (RD) Prevalence in a Country with a Limited Dataset: Which One Fits?

    Jul 1, 2025, 00:00

  • RWD166 Use of a Representative Sample of the French National Health Insurance Database (ESND) for Research: A Targeted Literature Review

    Jul 1, 2025, 00:00

  • HPR28 Interventions To Overcome the Challenges for Identifying Substandard, Spurious, Falsely Labeled, Falsified and Counterfeit Drugs (SSFFC). A Systematic Review

    Jul 1, 2025, 00:00

  • HPR34 Time to Access Trends of Pharmaceutical Products in EU4 and UK (2019-2021)

    Jul 1, 2025, 00:00

  • HSD26 Cancer Survivors and Opioid Use During Survivorship - A Scoping Review

    Jul 1, 2025, 00:00

  • MSR65 Development of Robust Comprehensive Code Lists to Ensure Consistency Across Global Real-World Evidence Studies

    Jul 1, 2025, 00:00

  • EE225 Cost Effectiveness Analysis of a Pharmacist-Led Clinical Decision Support System Powered by Machine Learning to Reduce Drug-Associated Acute Kidney Injury in the Adult Non-ICU Setting

    Jul 1, 2025, 00:00

  • RWD64 Real-Word Data on Long-Term Outcomes Among Adult Patients With Myopericarditis Related Heart Failure

    Jul 1, 2025, 00:00

  • HSD99 Geographic Inequities in Bariatric Surgery Access in Southern Chile: The Case of the Chilean Bundled Payment PAD

    Jul 1, 2025, 00:00

  • P46 Probabilistic Attribute Presentation in Discrete Choice Experiments (DCEs): A Review of Current Practice

    Jul 1, 2025, 00:00

  • PCR88 Patient Attitudes and Emotions Predict Health Outcomes: Evidence From the National Health and Wellness Survey

    Jul 1, 2025, 00:00

  • CO78 Clinical and Economic Burden of Non-Obstructive Hypertrophic Cardiomyopathy: A Literature Review

    Jul 1, 2025, 00:00

  • EPH74 Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population

    Jul 1, 2025, 00:00

  • HTA96 Navigating Evidence Requirements for Joint Clinical Assessment of Orphan and Advanced Therapy Medicinal Products in Europe

    Jul 1, 2025, 00:00

  • RWD29 A Retrospective Cohort Study Evaluating the Association Between Fibrosis-4 Index and Major Adverse Cardiovascular Events in Patients with Metabolic Dysfunction-Associated Steatohepatitis

    Jul 1, 2025, 00:00

  • HPR91 Perceptions of Private Health Insurance Among Households in a Small Island Developing State (SIDS): The Case of Grenada

    Jul 1, 2025, 00:00

  • The Argument-Based Approach to Validity Applied to Clinical Outcome Assessments: Some History and Notable Features

    Jul 1, 2025, 00:00

  • HTA15 Da Vinci Robotic-Assisted Surgery: 5 years of Health Technology Assessment Trends and Recommendations

    Jul 1, 2025, 00:00

  • PCR54 Preferences for Rapid Access Addiction Medicine Clinics Among Individuals with Problematic Alcohol Use A Discrete Choice Experiment

    Jul 1, 2025, 00:00

  • HPR147 Ongoing Accelerated Approval Trends and What It Means for Patients

    Jul 1, 2025, 00:00

  • HPR96 The Changing Impact of the Inflation Reduction Act on Payer Utilization Management- Insights from an Ongoing Quantitative Survey

    Jul 1, 2025, 00:00

  • EE248 Healthcare Resource Utilization of Adult Patients with Obesity Before vs. After GLP-1 Treatment in the United States Elective Outpatient Setting

    Jul 1, 2025, 00:00

  • RWD154 Healthcare Resource Utilization (HCRU) and Costs of Poly(ADP-ribose) Polymerase Inhibitors (PARPi) as First-Line Maintenance (1LM) Treatment for Ovarian Cancer (OC)

    Jul 1, 2025, 00:00

  • PCR101 Association of Chronic Conditions and Medication Burden with Patient Preferences for Long-Acting Antiretroviral Therapy in HIV Treatment

    Jul 1, 2025, 00:00

  • EPH59 Application of Prevalent New-User Cohort Designs to a Claims Data Study of Incidence of Nutritional Deficiency in People With Diabetes Using GLP-1 Receptor Agonists

    Jul 1, 2025, 00:00

  • PCR97 Recurrent Patient-Reported Outcome (PRO)-Based Symptomatic Deterioration Predicts Survival and Disease Progression in Patients With Resectable Non-Small Cell Lung Cancer (NSCLC): Post-Hoc Analysis of RATIONALE-315

    Jul 1, 2025, 00:00

  • EPH40 Association between Exposure to GLP-1 Treatment and Pancreatitis Risk in Obesity Patients: A Retrospective Database Study

    Jul 1, 2025, 00:00

  • HTA78 Assessing the Acceptance of Single-Arm Trials in Health Technology Appraisals: A Review of NICE, CADTH, HAS, and NCPE Appraisals in 2024

    Jul 1, 2025, 00:00

  • PT14 Do Breakthrough Therapies Demonstrate Breakthrough Value to Payers? An Evaluation of US Hemophilia B Gene Therapy Access Policies

    Jul 1, 2025, 00:00

  • MT12 Patient-Centric Factors in AI Chatbot Adoption for Healthcare

    Jul 1, 2025, 00:00

  • EPH32 Is there a GLP-1 Halo Effect? Potentially Better Overall Health Management Due to Starting GLP-1 for Weight Loss

    Jul 1, 2025, 00:00

  • EPH43 The Association Between COVID-19 Vaccination History and the Incidence of COVID-19 and Healthcare Resource Use in Rural Residents in Japan

    Jul 1, 2025, 00:00

  • EPH116 Informing Blood Donor Safety and Blood Supply Management in the United States: Factors Affecting Donor Time-To Return After Low Hemoglobin Deferral

    Jul 1, 2025, 00:00

  • HSD51 Premature Treatment Discontinuation Among Previously Untreated Medicare Beneficiaries With Chronic Lymphocytic Leukemia Treated With Oral Targeted Therapies: A Real-World Analysis

    Jul 1, 2025, 00:00

  • HPR22 Comparing Hospital Prices Paid by Commercial Insurance Plans at 340B vs. Non-340B Hospitals: Implications for Employers and Patients

    Jul 1, 2025, 00:00

  • PT3 An Artificial Intelligence (AI)-Assisted Systematic Literature Review (SLR) of the Economic Burden in Metastatic Pancreatic Adenocarcinoma: A Proof-of-Concept Study

    Jul 1, 2025, 00:00

  • EE389 Cost-Effectiveness of Pembrolizumab as First-Line Treatment for Patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (CRC) from Public Payer Perspective ...

    Jul 1, 2025, 00:00

  • HTA94 Investing in Clinical Guidelines to Enhance Health Technology Assessments and Reimbursement Decisions

    Jul 1, 2025, 00:00

  • EE277 Real-World Telehealth Utilization and Healthcare Costs in Commercially Insured Women With Breast Cancer: A Claims-Based Study

    Jul 1, 2025, 00:00

  • HTA35 Economic Analysis of an Optical Neonatal Skin Maturity Meter (MOMPN) in Brazilian Newborns

    Jul 1, 2025, 00:00

  • EPH24 Sodium Glucose Co-Transporter 2 Inhibitor Exposure and the Risk of Congenital Malformations: Nationwide Birth Cohort Study

    Jul 1, 2025, 00:00

  • HPR23 The Most Heavily Managed Drug Categories on Part D Formularies

    Jul 1, 2025, 00:00

  • HTA63 Trends in Use of Cost-Minimization Analyses in CDA-AMC Reimbursement Submissions

    Jul 1, 2025, 00:00

  • P18 Disparities in Antipsychotic Prescribing Among the US Medicare Population

    Jul 1, 2025, 00:00

  • HSD62 Ten-Year Trends in Potentially Inappropriate Sedative-Hypnotics and Pain Medication Use among Medicare Part D Beneficiaries

    Jul 1, 2025, 00:00

  • EPH186 Temporal Trends in Emergency Department Utilization for Opioid Use Disorder in Baltimore, Maryland

    Jul 1, 2025, 00:00

  • HSD60 Impact of Pharmacist Managed Pulmonary Arterial Hypertension Program on TYVASO Adherence

    Jul 1, 2025, 00:00

  • EE348 A Systematic Review of Economic Evaluations of Healthcare Associated Infection Prevention and Control Interventions in Long Term Care Facilities

    Jul 1, 2025, 00:00

  • MSR144 Physician-Augmented AI: Improving Machine Learning-Based Detection of NSCLC and Associated Clinical Indicators

    Jul 1, 2025, 00:00

  • RWD60 Evaluating Electronic Data Network and Direct Facility Retrieval Data Sources for Improved Patient Record Capture in Observational Studies

    Jul 1, 2025, 00:00

  • HSD112 Trends in Attainment of the Kidney Health Evaluation for Patients With Diabetes Measure Among Insured Individuals in the US, 2021-2024

    Jul 1, 2025, 00:00

  • HTA46 Fostering the Identification and Dissemination ofHealth Technology Assessment Studies: The Brazilian HTA Database Case Study

    Jul 1, 2025, 00:00

  • EE435 Integration of Environmental Considerations in Economic Evaluations: Significant Shift or Token Gesture? Insights From Severe Asthma Treatments

    Jul 1, 2025, 00:00

  • EE230 The Real-World Cost-Effectiveness of Faricimab Versus Existing and Future Biosimilars in Patients with Neovascular Age-Related Macular Degeneration in Canada

    Jul 1, 2025, 00:00

  • EPH64 Trends and Disparities in Weight Loss Activities Among Adults With Prediabetes and Obesity in the United States: 2009-2020

    Jul 1, 2025, 00:00

  • HTA89 Health Technology Assessment in Saudi Arabia - Expectations for Oncology Product Eligibility Based on Predicate Canadian HTA

    Jul 1, 2025, 00:00

  • HSD16 Describing the Amyotrophic Lateral Sclerosis US Population and Use of Supportive Aids and Interventions: Results from a Real-World Survey

    Jul 1, 2025, 00:00

  • MSR73 Augmenting Small Training Datasets Improves Machine Learning Prognostic Performance

    Jul 1, 2025, 00:00

  • P30 Navigating Real-World Data (RWD) Complexities: Operational Assessment Strategy to Identify Fit-For-Purpose Data Sources for Real-World Evidence (RWE) Studies With Regulatory Purpose (OASIS)

    Jul 1, 2025, 00:00

  • PCR205 What Is the Level of Agreement between Family Caregivers and Their Children Living with Rheumatic Disease in Reporting Health-Related Quality of Life?

    Jul 1, 2025, 00:00

  • HPR39 Health Insurance Use Among Young Pharmacists in Nigeria

    Jul 1, 2025, 00:00

  • CO41 Real-world Clinical And Demographic Characteristics Associated With Progression To Type 2 Diabetes In Patients With Prediabetes

    Jul 1, 2025, 00:00

  • RWD78 Psychotropic Medication Treatment Patterns in Employee Dependents with Autism Spectrum Disorder

    Jul 1, 2025, 00:00

  • MSR143 Developing a Large Language Model-Based Simulation for PT Committees: Methodology and Inputs for Realistic Dynamics

    Jul 1, 2025, 00:00

  • SA6 Changes in HbA1c and Body Weight in US Adults With Type 2 Diabetes and Chronic Kidney Disease Who Received Oral Semaglutide

    Jul 1, 2025, 00:00

  • RWD93 Programmed Death Ligand 1 (PD-L1) Protein Expression Among Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma from Two Oncologic Institutions in Brazil

    Jul 1, 2025, 00:00

  • EE260 A Real-World Analysis of Patient Cost Burden From COPD and Its Treatment Regimens

    Jul 1, 2025, 00:00

  • A Scoping Review of Interventions to Reduce the Environmental Footprint of Healthcare

    Jul 1, 2025, 00:00

  • EPH107 Patient-Provider Herpes Zoster Vaccination Discussion: Insights From Observed Primary Care Visits in the United States

    Jul 1, 2025, 00:00

  • HTA74 Transforming Global Value Dossier (GVD) Drafting: Creation with a Generative Artificial Intelligence (Gen AI)-Driven Coauthoring Accelerator

    Jul 1, 2025, 00:00

  • P35 Integrating Patient-Reported Outcomes in Clinical Care - Opportunities and Roadblocks From the Patient Perspective: A Scoping Review

    Jul 1, 2025, 00:00

  • MSR17 A Comparative Assessment of LLM Agreement for Clinical Data Extraction Tasks

    Jul 1, 2025, 00:00

  • HTA2 Role of Relative Dose Intensity in Health Economic Evaluations: A Review of National Institute for Health and Care Excellence Technology Appraisals of Treatments in Solid Tumors

    Jul 1, 2025, 00:00

  • HTA50 A Reanalysis of Canada's Drug Agency (CDA) Reports: Do Conclusions from Cost-Effectiveness Analyses Using Quality-Adjusted Life-Years (QALYs) Hold When Evaluating with Equal Value of Life-Years Gained (evLYG)?

    Jul 1, 2025, 00:00

  • PT17 Challenges for PAIC in Rare Diseases: Results of a Systematic Literature Review

    Jul 1, 2025, 00:00

  • CO5 Patient Journey Prior to the Diagnosis of Niemann-Pick Disease Type C

    Jul 1, 2025, 00:00

  • EE333 A Budget Impact Analysis of Introducing OPSYNVI for the Treatment of Adult Patients Diagnosed With Pulmonary Arterial Hypertension

    Jul 1, 2025, 00:00

  • HPR40 Determinants of FDA Review Duration for Novel Therapeutics: Analysis of Regulatory Designations and Product Characteristics

    Jul 1, 2025, 00:00

  • HTA84 Payer Perceptions on Creating a National Value assessment Body in the US

    Jul 1, 2025, 00:00

  • MT27 Impact of Single-Patient use Electrocardiogram Monitoring in the Cost of Care and Infection Prevention of CABG Surgery Patients in the USA

    Jul 1, 2025, 00:00

  • PCR218 Content Validation of the Most Bothersome Symptom - Essential Tremor Questionnaire (MBS-ET): A Cognitive Debriefing Study

    Jul 1, 2025, 00:00

  • HPR52 Digital twins: Hype or Hope for Better Health Outcomes?

    Jul 1, 2025, 00:00

  • HTA19 The Impact of Meeting Orphan Criteria on Reimbursement Decisions and ICERs in Scotland

    Jul 1, 2025, 00:00

  • EE463 A Longitudinal Year-by-Year Cost Analysis for Patients Diagnosed with Polycythemia Vera

    Jul 1, 2025, 00:00

  • MT21 A New-to-Market Single-Use Ureteroscope: Urologist Performance Rating and Capability Assessment

    Jul 1, 2025, 00:00

  • HPR82 Real-World Evidence in FDA and EMA Regulatory Reviews: Insights on Its Role in Submission Packages and Approvals

    Jul 1, 2025, 00:00

  • MSR80 Evaluation of Marginal Healthcare Expenditures and Health-related Quality of Life in Multiple Sclerosis with a Bayesian Quantile Machine Learning Approach

    Jul 1, 2025, 00:00

  • EE309 Examination of the Two-Year US Commercial Payer Budget Impact (BI) of the Leva Pelvic Health System, a Prescription Medical Device That Provides Supervised Pelvic Floor Muscle Training (PFMT) As First-Line Treatment for Female Urinary ...

    Jul 1, 2025, 00:00

  • MT38 Does a Digital Health Program Influence One’s Choice of Traditional Health Care? Changes in Health Care Use and Episodic Cost Among a Group of Chronic MSK Patients in a Digital Conservative Musculoskeletal Care Program

    Jul 1, 2025, 00:00

  • RWD7 Youth Mental Health Crisis: Economic Impacts and HEOR Opportunities

    Jul 1, 2025, 00:00

  • RWD156 Validation of Real-World Recurrence-Free Survival (rwRFS) and Distant Metastasis-Free Survival(rwDMFS) Endpoints in Early-Stage Melanoma

    Jul 1, 2025, 00:00

  • RWD44 Clinical Validation of Large Language Model for Automated Extraction of Genetic Testing Data

    Jul 1, 2025, 00:00

  • HTA59 Revisiting Archetypes: New Archetypes for Strategic Global Value Evidence Planning

    Jul 1, 2025, 00:00

  • HSD25 Efficacy of Improvisational Communication Training for Health Workers in Emergency Care Unit in Hungary: Quazy Experimental Study

    Jul 1, 2025, 00:00

  • MSR119 Assessing the Impact of PD-L1 and BRAF Biomarkers on Long-Term Survivorship (LTS) Rates Among Treatment-Naive Advanced Melanoma Patients Receiving Immune Checkpoint Inhibitors (ICIs)

    Jul 1, 2025, 00:00

  • MT39 Real-World Clinical Outcomes, Healthcare Resource Utilization, and Direct Medical Costs in Atrial Fibrillation Patients Receiving Catheter Ablation in Japan

    Jul 1, 2025, 00:00

  • HTA28 Health Equity and HTA: Is Equity Data Shaping Recommendations

    Jul 1, 2025, 00:00

  • Psychometric Performance of a New Condition-Specific Preference-Weighted Measure, Vision Impairment in Low Luminance-Utility Index, and EQ-5D-5L in Patients With Age-Related Macular Degeneration: A MACUSTAR Study Report

    Jul 1, 2025, 00:00

  • MSR61 Psychometric Validation of the Sunlight Exposure Diary and Erythropoietic Protoporphyria Impact Questionnaire (EPIQ) Using Data from the AURORA Clinical Study in Erythropoietic Protoporphyria (EPP)

    Jul 1, 2025, 00:00

  • EE351 Cost-Utility Analysis of Sequential Therapy of iCT IRd and DRd strategy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant-Ineligible in China

    Jul 1, 2025, 00:00

  • Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States

    Jul 1, 2025, 00:00

  • HTA64 Validation of Artificial Intelligence (AI) Tool to Identify PICO Questions for EU Joint Clinical Assessment (JCA)

    Jul 1, 2025, 00:00

  • EE335 Economic Burden of Hwabyeong in South Korea: An Analysis of Direct, Non-Medical, and Indirect Costs

    Jul 1, 2025, 00:00

  • MSR136 Augmenting Race and Ethnicity in a Real-World Oncology Cohort Using the Bayesian Improved Surname Geocoding Methodology

    Jul 1, 2025, 00:00

  • P63 Balancing Innovation and Affordability: Analyzing the Cost of Drugs for Rare Diseases in Canada

    Jul 1, 2025, 00:00

  • EE231 The Real-World Cost-Effectiveness of Faricimab Versus Existing and Future Biosimilars in Patients with Neovascular Age-Related Macular Degeneration in the UK

    Jul 1, 2025, 00:00

  • PCR227 Mapping the NEI-VFQ-25 to the EQ-5D-Y-3L and CHU-9D among High School Students with Myopia in China

    Jul 1, 2025, 00:00

  • EE522 Long-Term Cost-Effectiveness Analysis of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogues in Patients With Type 2 Diabetes in China

    Jul 1, 2025, 00:00

  • HSD111 Provider perspectives on the DREAMM-7 Trial Results and Belantamab Mafodotin (belamaf) in Combination with Bortezomib and Dexamethasone (B-Vd) as a Potential Treatment for Patients with Relapsed or Refractory Multiple Myeloma (R/R MM ...

    Jul 1, 2025, 00:00

  • PCR149 Patient Optimism and the Trade-Off Between Kidney Quality and Waiting Time

    Jul 1, 2025, 00:00

  • EE275 Economic Evaluation of Adjuvant Chemotherapy for Soft Tissue Sarcoma Using Linked NETSARC+ (French Registry) and SNDS (French National Health Data System) Real World Data: The Deepsarc Study

    Jul 1, 2025, 00:00

  • RWD55 A Large Language Model Approach for Evaluating Real-World Evidence in FDA Approvals

    Jul 1, 2025, 00:00

  • HPR98 Long-term Sustainability of National Essential Medicines Policy in Primary Care System in Rural Southwestern China from 2012-2017: Discrepancies by Facilities and Medicines

    Jul 1, 2025, 00:00

  • EPH31 Prevalence of Hypertension Over (Calendar) Time Among People With Narcolepsy Treated With Oxybate

    Jul 1, 2025, 00:00

  • HPR26 Are Existing Descriptions of Unmet Medical Need Fit for Purpose in the CMS Drug Negotiation Program Context?

    Jul 1, 2025, 00:00

  • CO49 Prognostic or Predictive Factors in Biliary Tract Cancer: A Systematic Literature Review

    Jul 1, 2025, 00:00

  • RWD133 Building on ‘Contemporary Practice and Considerations for Real-World Data (RWD) Source Identification and Feasibility Assessment’: Mapping Feasibility Criteria Across 46 Real-World Evidence (RWE) Guidelines

    Jul 1, 2025, 00:00

  • HPR154 The Impact of the Inflation Reduction Act on Rare Diseases and Orphan Drugs

    Jul 1, 2025, 00:00

  • HTA70 A Review of NICE UK Submissions for Antibody-Drug Conjugates in Oncology

    Jul 1, 2025, 00:00

  • PCR57 Investigating the Potential of Extracting Answers to Health-Related Quality of Life Questionnaires From Patient Community Data

    Jul 1, 2025, 00:00

  • HPR51 Real-World Evidence in FDA Approvals for Labeling Extension of Drugs and Biologics

    Jul 1, 2025, 00:00

  • RWD18 Treatment Patterns and Healthcare Resource Utilization in Patients Diagnosed With CRSwNP in HMO From Colombia: A Real Word Evidence Study

    Jul 1, 2025, 00:00

  • EPH113 Characteristics of Patients Initiating Wegovy (Semaglutide) for Cardiovascular Risk Reduction in a Medicare Population

    Jul 1, 2025, 00:00

  • HPR8 Healthcare Across Borders: Changes in Physician Numbers and Spatial Inequalities in Hungary and the DACH Countries (Austria, Germany, Switzerland)

    Jul 1, 2025, 00:00

  • EE255 Economic Impact of Recurrence in High-Risk Early-Stage Estrogen-Receptor Positive (ER+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer (BC)

    Jul 1, 2025, 00:00

  • EE322 Cost and Clinical Characteristics of Acute Pancreatitis Hospitalizations Related and Unrelated to Hypertriglyceridemia

    Jul 1, 2025, 00:00

  • PCR34 More than "financial toxicity": the Socioeconomic Impact of Cancer and Cancer Care on Patients and Their Relatives

    Jul 1, 2025, 00:00

  • MT22 Hope as a Catalyst: AI-Based Conversational Agents in Mental Health Support

    Jul 1, 2025, 00:00

  • CO27 Progression-Free Survival (PFS) as a Surrogate for Overall Survival (OS) in the Front-Line Maintenance Setting for Advanced Ovarian Cancer (OC): A Trial-Level Meta-Analysis

    Jul 1, 2025, 00:00

  • MT17 Digital Health Interventions and Environmental Sustainability: A Targeted Literature Review

    Jul 1, 2025, 00:00

  • PCR190 Impact of Valbenazine on Improvements in Disability and Functional Impairment in Patients With Tardive Dyskinesia (TD): Sheehan Disability Scale (SDS) Results From a Phase 4 Randomized Withdrawal Study (NCT03891862)

    Jul 1, 2025, 00:00

  • EE524 Millions in Annual National Savings Could Be Realized From Improving the Quality of Uterotonic Medications in Sub-Saharan Africa

    Jul 1, 2025, 00:00

  • PCR153 The Vaccine Activation Measure (VAM™): Validation of a New Segmentation Tool for Understanding Vaccine Hesitance and Confidence

    Jul 1, 2025, 00:00

  • HSD104 Colorectal Cancer Screening Initiation Among Newly Age-Eligible Medicaid-Insured Individuals in Texas

    Jul 1, 2025, 00:00

  • HPR127 Evolution of Technology Diffusion Within Brazilian Universal Healthcare System (Sistema Único De Saúde – SUS) 2+ Years After Listing of Antiangiogenics Treatment for Diabetic Macular Edema (DME)

    Jul 1, 2025, 00:00

  • MSR74 Data Extraction from Full-Text PDFs Using Large Language Models for Systematic Reviews

    Jul 1, 2025, 00:00

  • PT16 Assessing the Impact of Disparity on Hospital Outcomes: Review of 5 Diseases and their Unique Challenges

    Jul 1, 2025, 00:00

  • HSD65 Telehealth Use Among Adultswith Sickle Cell Disease in Texas Medicaid Before and During the Covid-19 Pandemic

    Jul 1, 2025, 00:00

  • PCR85 The Socioeconomic Impact of Cancer and Cancer Care on Patients and Their Relatives: Assessing the Content Validity of Dedicated Patient-Reported Outcomes Measurement (PROM) Instruments

    Jul 1, 2025, 00:00

  • PT24 A Quantitative Exploration of Challenges to the Sustainability of the United States Biosimilar Market

    Jul 1, 2025, 00:00

  • EE330 Correlation Between Price and Prevalence in Non-Oncology Orphan Products With Recent Trends (2015-2024)

    Jul 1, 2025, 00:00

  • PCR44 Characterizing the Experience of Excessive Daytime Sleepiness in Patients with Idiopathic Hypersomnia: Implications for Measuring Daytime Sleepiness with the Epworth Sleepiness Scale in a Clinical Trial (NCT05156047)

    Jul 1, 2025, 00:00

  • HPR153 The Reimbursement Status of Ustekinumab Across HTAs: A Global Perspective

    Jul 1, 2025, 00:00

  • EE414 Impact Analysis of Statin Discontinuation on Healthcare Resource Utilization (HCRU) and Cost of Care in Patients With Atherosclerotic Cardiovascular Disease (ASCVD) in the US

    Jul 1, 2025, 00:00

  • PCR251 Is There Value in Knowing? Perspectives of Cancer Screening Outcomes Among the US General Population

    Jul 1, 2025, 00:00

  • EPH139 How is Patient Safety Addressed in Pharmacy Degree Programs in Brazil?

    Jul 1, 2025, 00:00

  • EE451 Assessing the Operational Efficiency of a Vial Filling Robot in an Outpatient or a Community Pharmacy

    Jul 1, 2025, 00:00

  • EE270 Cost-Effectiveness Analysis of Tisagenlecleucel for Third-Line Treatment With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

    Jul 1, 2025, 00:00

  • EE474 Modeling the Potential Public Health Impact and Cost-Effectiveness of BNT162b2 COVID-19 Adapted Booster Vaccination in Guatemala

    Jul 1, 2025, 00:00

  • EE280 Clinical and Economic Analysis in Rheumatoid Arthritis Treatment: A Managed Care Experience

    Jul 1, 2025, 00:00

  • HPR125 Increasing Recognition Towards Inclusion of Patient Preferences in Healthcare Intervention Development and Access- Current Landscape and Way Forward

    Jul 1, 2025, 00:00

  • CO40 Real-World Patient Characteristics and Treatment Patterns in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Long-Term Survivorship

    Jul 1, 2025, 00:00

  • EE438 Budget Impact Analysis of Lanadelumab Versus C1 Inhibitor for Hereditary Angioedema Long Term Prophylaxis: A Brazilian Private Sector Perspective

    Jul 1, 2025, 00:00

  • PCR56 Translation and Cultural Adaptation of the Pain Impact Questionnaire (PIQ-6) Among Chronic Pain Patients in Japan

    Jul 1, 2025, 00:00

  • EPH126 Identify the Adverse Drug Reactions Among Rheumatoid Arthritis Patients Being Administered Specific Classes of Disease-Modified Anti-Rheumatic Drugs (DMARDs)

    Jul 1, 2025, 00:00

  • OP9 Budget Impact Model of Enhanced Lung Cancer Screening With AI/ML Tech-Based Software as a Medical Device (SaMD) on a US Cohort and Private Payer Perspective

    Jul 1, 2025, 00:00

  • HTA14 Empowering Healthcare Decision-Making: Leveraging Standardized Template for Enhanced Reliability and Efficiency in Budget Impact Analysis by Health Technology Assessment Agency

    Jul 1, 2025, 00:00

  • PCR130 Health-Related Quality of Life (HRQoL) of Large B-cell Lymphoma (LBCL) and Follicular Lymphoma (FL) Patients Treated with Axicabtagene Ciloleucel (Axi-cel) in Clinical Trials and the Real-World: A Targeted Literature Review

    Jul 1, 2025, 00:00

  • RWD70 Barriers to Genetic Risk Factor Molecular Testing in CLL: An Analysis of Real-World Practice and Alignment with 2023 Guidelines in Germany

    Jul 1, 2025, 00:00

  • CO16 The Impact of Glucocorticoid (GC) Dose on Clinical Outcomes in Congenital Adrenal Hyperplasia (CAH): A Systematic Literature Review (SLR)

    Jul 1, 2025, 00:00

  • RWD170 The Pen That Makes You Leaner: GLP-1 Prescription Trends for Weight Loss in the US

    Jul 1, 2025, 00:00

  • RWD53 Burden of Illness and Healthcare Resource Utilization (HCRU) for Chronic Obstructive Pulmonary Disease (COPD) in Ontario, Canada

    Jul 1, 2025, 00:00

  • P53 Alignment Between CDA Recommendations and pCPA Negotiation Outcomes: Exploring Factors Influencing Reimbursement Success

    Jul 1, 2025, 00:00

  • PCR71 Insights from a Shared-Decision Making Appointment Preparation Process in an Eczema Self-Monitoring Mobile Health App

    Jul 1, 2025, 00:00

  • EE391 Investing in Optimized HIV Prevention Among Young Men Who Have Sex With Men in Brazil: Insights From Fiscal Health Modeling

    Jul 1, 2025, 00:00

  • MSR153 Frequently Asked Questions (FAQs): What Are the Risks and Mitigation Strategies in Using Gen-AI in HEOR?

    Jul 1, 2025, 00:00

  • EPH123 An Epidemiological Assessment of the Stroke Burden in Hungary Using Data From the Global Burden of Disease Study (1990–2021)

    Jul 1, 2025, 00:00

  • HSD87 Chimeric Antigen Receptor T Cell (CAR T) Therapy As Second-Line (2L) Treatment for Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Therapy Choice and Treatment Barriers Among US Oncologists

    Jul 1, 2025, 00:00

  • P49 A Health Technology Assessment Framework for Ethics Analysis in Drug Reimbursement Reviews at Canada's Drug Agency

    Jul 1, 2025, 00:00

  • EPH154 Racial Differences in Health Status Among Newly Diagnosed Type 2 Diabetes

    Jul 1, 2025, 00:00

  • EE430 Medicare Cost Comparison of Transcarotid Artery Revascularization (TCAR) Versus Transfemoral Carotid Artery Stenting (TF-CAS)

    Jul 1, 2025, 00:00

  • PCR24 Impact of Herpes Zoster Ophthalmicus on Healthcare Utilization and Patient Reported Outcomes: Results from a Multicenter Cohort Study

    Jul 1, 2025, 00:00

  • MSR155 Assessing the Effectiveness of Large Language Models in Automating Systematic Literature Reviews: Findings from Recent Studies

    Jul 1, 2025, 00:00

  • EPH8 Natural History and Burden of Disease Among Patients With Juvenile GM2 Gangliosidoses in France

    Jul 1, 2025, 00:00

  • EPH158 National Assessment of Depression Between Early vs Late Adolescents Using National Survey of Child Health Survey

    Jul 1, 2025, 00:00

  • P26 VBA and R to Automate Health Economic Model Programming

    Jul 1, 2025, 00:00

  • RWD81 The Economic Burden of Illness for Patients with Idiopathic Pulmonary Fibrosis Utilizing Treatment Cohorts: A US Retrospective Claims Study

    Jul 1, 2025, 00:00

  • EE398 Cost Comparison of Osimertinib Plus Chemotherapy Versus Amivantamab Plus Lazertinib for the First-Line Treatment of Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC

    Jul 1, 2025, 00:00

  • HSD98 Bariatric Surgery Costs in Chile: Cost of a Comprehensive, Evidence-Based, and High-Quality of Care Program

    Jul 1, 2025, 00:00

  • RWD144 Travel Burden of Beta-Thalassemia Patients Receiving Red Blood Cell Transfusions in the Brazilian Public Healthcare System: A Real-World Study

    Jul 1, 2025, 00:00

  • HPR61 US Food and Drug Administration Authorizations of Therapeutic Biologics and Biosimilars, 1980-2024

    Jul 1, 2025, 00:00

  • MSR21 Do Lifetables Overestimate Non-Cancer-Specific Survival (NCSS) in Oncology? A Case Study From Treatment-Naïve Advanced Melanoma

    Jul 1, 2025, 00:00

  • RWD1 Hemoglobin Levels and Social Determinants of Health as Risk-factors of End-Organ Damage in Sickle Cell Disease: A Retrospective Analysis

    Jul 1, 2025, 00:00

  • MSR104 Revolutionizing Multi-Level Network Meta-Regression: Advancing Analysis With the Package

    Jul 1, 2025, 00:00

  • EE250 Quantifying Spillover Impacts: Effect of Novel Therapies for IgA Nephropathy on Patients Awaiting Kidney Transplant

    Jul 1, 2025, 00:00

  • PCR45 Rethinking Women's Health: Unpacking the 2024 Women's Health Research Roadmap With a Landscape Review of Clinical Outcome Assessments (COA), Health Agency Recommendations and Drug Label Claims With COA Related to Women's Health

    Jul 1, 2025, 00:00

  • EE236 A Health Economic Evaluation of an Artificial Intelligence-Assisted Prescription Review System in a Real-World Setting in China

    Jul 1, 2025, 00:00

  • MSR126 Data-Based Lumping and Splitting of Treatments in Network Meta-Analysis in the Presence of Heterogeneity: A Flexible Non-Parametric Bayesian Approach

    Jul 1, 2025, 00:00

  • HPR150 Review of Cell Therapy Access Landscape

    Jul 1, 2025, 00:00

  • HSD70 Importance of Virtual Access for Mental Health Services: Evidence from ESI Population

    Jul 1, 2025, 00:00

  • EE305 Cost-Effectiveness of Maribavir for Post-Transplant Refractory (With or Without Resistance) Cytomegalovirus Infection in China

    Jul 1, 2025, 00:00

  • P55 Access to Care and Ability to Afford Prescription and Medical Treatment Among Adults With Obesity in the United States

    Jul 1, 2025, 00:00

  • HPR86 Economic Burden of Non-Pharmacological Treatment in Amyotrophic Lateral Sclerosis in Brazil's Public Healthcare System: A 2022 Real World Cost Analysis

    Jul 1, 2025, 00:00

  • HTA7 Use of Health Technology Assessments in Specialty Drug Coverage Decisions by U.S. Commercial Health Plans

    Jul 1, 2025, 00:00

  • EE354 Impact of Capacity and Resource Constraints on Wet Age-Related Macular Degeneration and Diabetic Macular Edema in the Brazilian Public Healthcare System: an Individual-Level Microsimulation Study

    Jul 1, 2025, 00:00

  • PCR231 Beyond the Numbers: Measuring the Real-Life Impact of Medical Treatments via Patient-Level Modeling

    Jul 1, 2025, 00:00

  • EE453 Cost-Effectiveness Analyses of Repotrectinib in TKI-Naïve Patients with ROS1+ Advanced Non-Small Cell Lung Cancer

    Jul 1, 2025, 00:00

  • CO93 Real-World Healthcare Resource Utilization in Patients with Idiopathic Pulmonary Fibrosis initiating Antifibrotic Therapy in the Medicare Fee-For-Service Population

    Jul 1, 2025, 00:00

  • PCR137 Patient and Physician Perspectives on Attributes of IO-Containing? Perioperative Treatments in Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer (NSCLC)

    Jul 1, 2025, 00:00

  • EPH2 National Assessment of Breast and Cervical Cancer Screening Using National Health Interview Survey

    Jul 1, 2025, 00:00

  • PCR87 Analysis of the Effect of Trofinetide Treatment on the Domain and Item-Level Responses of the Rett Syndrome Behavior Questionnaire Using Data From the LAVENDER Trial

    Jul 1, 2025, 00:00

  • PCR211 Patient, Caregiver, and Physician Perspectives on the Burden of Disease Chronic Refractory Gout and Its Treatment: Concept Elicitation

    Jul 1, 2025, 00:00

  • EPH138 Dynamic Population Modelling Indicates a Flavored EVP Ban in the UK May Negatively Impact Population Health

    Jul 1, 2025, 00:00

  • CO90 What Does the Pan-Asian Evidence for Malignant Robotic-Assisted Procedures With da Vinci Surgical Systems Say? A systematic Literature Review and Meta-Analysis

    Jul 1, 2025, 00:00

  • RWD61 Assessing Antipsychotic Adherence in People With Cognitive Impairment Associated With Schizophrenia: A US Non-Interventional Cohort Study of Real-World Data

    Jul 1, 2025, 00:00

  • PCR69 Examination of Factors Influencing Colorectal Screening Participation

    Jul 1, 2025, 00:00

  • PCR115 Qualitative Assessment of the Idiopathic Hypersomnia Severity Scale: Suitability for Use As a Clinical Trial Endpoint as Demonstrated in NCT05156047

    Jul 1, 2025, 00:00

  • PCR258 Humanistic Burden in Metastatic Triple-Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR)

    Jul 1, 2025, 00:00

  • EE339 Evaluating the Impact of Predictive Variables on Individual Biosimilar US Market Share

    Jul 1, 2025, 00:00

  • PCR213 Use of Personalized Migraine Summary Reports in a Symptom Tracking Program to Support Migraine Self-Management

    Jul 1, 2025, 00:00

  • MSR75 Comparison of Generative AI and Manual Data Programming in a Lupus Health Productivity Loss Study

    Jul 1, 2025, 00:00

  • RWD103 Real-World Biologic Prescribing Patterns and Reasons for Discontinuation in Patients with UC and CD

    Jul 1, 2025, 00:00

  • EE374 Cost-Effectiveness Analysis of Dostarlimab Plus Chemotherapy As First-Line Treatment for Metastatic Non-Squamous Non-Small Cell Lung Cancer in Japan

    Jul 1, 2025, 00:00

  • CO79 Estimating the Effect of a Discontinued Amyotrophic Lateral Sclerosis Treatment on Time-to-Death Using Sequential Target Trial Emulation

    Jul 1, 2025, 00:00

  • EPH156 Evaluation of Chronic Conditions and Severe Outcomes in Adults Aged 18-59 Years With Medically Attended RSV Illness Using U.S. Commercial Claims Data

    Jul 1, 2025, 00:00

  • PCR186 JAV-RARAS: Evaluation of Adherence to Clinical Protocol and Therapeutic Guidelines (PCDT) for Mucopolysaccharidosis Type 2 (MPS2) at Codajás Polyclinic - An Analysis of the Value-Based Care Journey

    Jul 1, 2025, 00:00

  • HPR67 Canada’s Evolving Market for Biosimilars and What It Means for Payers

    Jul 1, 2025, 00:00

  • PCR98 Enhancing Healthcare Quality through Patient-Centered Outcome Measures in Medicare's Merit-based Incentive Payment System

    Jul 1, 2025, 00:00

  • HTA29 Who Benefits From Technological Progress Among People With Type 1 Diabetes? Improvements in Glycemic Outcomes After CGM Adoption by Sociodemographic Characteristics

    Jul 1, 2025, 00:00

  • EE511 Descriptive Analysis Of Patients With Psoriasis (PSO) Using Biologics Vs. Non-biologics

    Jul 1, 2025, 00:00

  • EPH26 Mortality due to Road Traffic Injuries in Colombia Before and After SARS-CoV-2 (2018-2022)

    Jul 1, 2025, 00:00

  • EPH171 Gabapentinoid Use, Potential Misuse, and Associated Risk Factors among U.S. Adult Cancer Survivors: A Retrospective Cohort Study

    Jul 1, 2025, 00:00

  • EE267 Cost-Effectiveness of Dostarlimab in the Treatment of Newly Diagnosed Patients with Locally Advanced Rectal Cancer: Early Economic Modelling

    Jul 1, 2025, 00:00

  • HPR99 Racial and Ethnic Disparities in Orphan Drug Utilization Among Medicare Beneficiaries

    Jul 1, 2025, 00:00

  • PCR143 Psychometric Validation of the Modified Low Luminance Questionnaire in Patients With X-Linked Retinitis Pigmentosa

    Jul 1, 2025, 00:00

  • PCR13 Content Validation of the Patient Attainment Scale-Essential Tremor (PAS-ET): A Novel Patient-Reported Outcome Measure Assessing Patient-Level Perceptions of the Importance, Current Function and Definitions of Meaningful Improvement i ...

    Jul 1, 2025, 00:00

  • CO44 Comparative Risk of Major Adverse Cardiovascular Events among Patients who Initiate Treatment with Acute Migraine Agents

    Jul 1, 2025, 00:00

  • CO8 Evaluating the Effects of the COVID-19 Pandemic on ICU Mortality and Sedation Charges in Mechanically Ventilated Patients

    Jul 1, 2025, 00:00

  • P22 Assessment of Reasoning Agents for building Literature Search Strategies

    Jul 1, 2025, 00:00

  • EE215 Pompe Disease in Sweden: A Real-World Evidence Study Investigating Healthcare Resource Utilisation and Costs

    Jul 1, 2025, 00:00

  • Identifying the Influential Dynamic Inputs in Cost-Effectiveness Analyses

    Jul 1, 2025, 00:00

  • EE436 Real World Healthcare Resource Utilization (HRU) and Costs Associated With Mantle Cell Lymphoma (MCL) Therapies in the Frontline (1L) and Relapsed/Refractory (R/R) Setting

    Jul 1, 2025, 00:00

  • CO67 The Potential Long-Term Comparative Effectiveness of Larotrectinib vs Repotrectinib for Treatment of NTRK Gene Fusion-Positive Cancers

    Jul 1, 2025, 00:00

  • PCR92 Renal Cell Carcinoma and Muscle Invasive Bladder Cancer Patients' Perception of Risk and Fear of Recurrence

    Jul 1, 2025, 00:00

  • CO35 Predicted Effectiveness of First- and Second-Line Treatment Sequences in Advanced or Recurrent Endometrial Cancer

    Jul 1, 2025, 00:00

  • EPH162 Real-World Demographic and Clinical Characteristics of Patients With Atherosclerotic Cardiovascular Disease With or Without Chronic Kidney Disease or Systemic Inflammation in the United States

    Jul 1, 2025, 00:00

  • HSD75 Evaluating the Association Between Medicare Star Ratings Part D Medication Adherence Measures and the Part C Plan All-Cause Readmission Outcome Measure

    Jul 1, 2025, 00:00

  • OP8 Framework for Real-World Data Used in Regulatory Submissions

    Jul 1, 2025, 00:00

  • MSR14 Frailty Indices Using Claims Data - Examples from a Hospitalized Medicare Population

    Jul 1, 2025, 00:00

  • MSR146 Identifying Redundant or Misfitting Items Using Item Response Theory: Type I and II Error Rates for Item Local Dependence and Misfit Detection in Clinical Outcome Assessments

    Jul 1, 2025, 00:00

  • EE216 Health and Economic Impact Analysis of Uncontrolled Hemophilia Patients in Colombia

    Jul 1, 2025, 00:00

  • EE477 Healthcare Costs and Resource Utilization Associated With Knee Osteoarthritis and Obesity in the United States: A Retrospective Database Study

    Jul 1, 2025, 00:00

  • HSD37 Characteristics of Patients Enrolled in a Pharmacist Managed Rare Disease Program: Highlighting National Diversity and Representation

    Jul 1, 2025, 00:00

  • HPR73 Analysis of Out-of-Pocket Payments Associated with Female Infertility in Hungary Between 2015-2023

    Jul 1, 2025, 00:00

  • PCR6 Impacts of Annual Wage on Insulin Adherence in Diabetes

    Jul 1, 2025, 00:00

  • P50 Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection

    Jul 1, 2025, 00:00

  • PCR245 Inclusion of Health-Related Quality of Life (HRQoL) and Other Patient-Reported Outcomes (PROs) in the United States Food and Drug Administration (FDA) Labels

    Jul 1, 2025, 00:00

  • PCR61 Exploring the Health and Well-being of Pediatric Caregivers within Chinese Cultural Contexts: A Systematic Review of Qualitative Studies from Chinese Databases

    Jul 1, 2025, 00:00

  • EE240 Economic Impact of Blister-Packaging on Medication Adherence in First-Line Multiple Myeloma Treatment

    Jul 1, 2025, 00:00

  • HTA42 Better Off Dead: Mitigating For Situations Where Improving Survival Isn't Cost-Effective

    Jul 1, 2025, 00:00

  • P56 Biosimilar Optimization in Community Oncology Practices

    Jul 1, 2025, 00:00

  • PCR194 Qualitative Evaluation of a Tool for Collecting Stated and Revealed Patient Preferences in the Context of Atypical Antipsychotics for the Treatment of Depression or Bipolar Disorder in Adults

    Jul 1, 2025, 00:00

  • MSR46 Evaluation of Machine Learning Assisted Title and Abstract Screening in 5 Clinical Systematic Literature Reviews

    Jul 1, 2025, 00:00

  • RWD172 Implementation of New Real-World Data Quality Frameworks and Initiatives to Address Challenges in Oncology Electronic Health Record (EHR)-Derived Databases for Research

    Jul 1, 2025, 00:00

  • EE434 An Economic Model to Estimate Costs of Adverse Events in Patients Treated With Lisocabtagene Maraleucel (liso-cel), Axicabtagene Ciloleucel (axi-cel), or Tisagenlecleucel (tisa-cel) for Relapsed/Refractory Follicular Lymphoma

    Jul 1, 2025, 00:00

  • HPR70 Revisiting Conflicts in Population-Adjusted Indirect Comparisons: A Duality Perspective

    Jul 1, 2025, 00:00

  • HTA8 Trends in Indirect Treatment Comparison (ITC) Methods Used in Reimbursement Submissions in Canada and the US

    Jul 1, 2025, 00:00

  • EE288 Economic Burden and Healthcare Resource Utilization (HCRU) Associated with High-Risk Papillary Stage Ta T1 (PAPTa1) Non-Muscle Invasive Bladder Cancer (NMIBC) Patients, 2008-2019

    Jul 1, 2025, 00:00

  • CO94 Impact of Individualized Neoantigen Therapies on Health, Productivity and Health System Capacity Outcomes in Resectable Melanoma in England

    Jul 1, 2025, 00:00

  • RWD40 Real World Treatment Patterns for Castration-Sensitive Prostate Cancer Between 2012 and 2024 : A Systematic Review

    Jul 1, 2025, 00:00

  • RWD106 Cardiovascular Morbidity and Mortality Among ATTR-CM Patients Treated with Tafamidis in the US

    Jul 1, 2025, 00:00

  • PCR184 Measuring and Reporting Health-Related Quality of Life (HRQoL) in Locally Advanced/Metastatic Urothelial Cancer (La/mUC) Research: Capturing Outcomes That Really Matter to Patients

    Jul 1, 2025, 00:00

  • EE229 Cost-Effectiveness Analysis of First-Line Tremelimumab Plus Durvalumab Versus Sorafenib in Unresectable Hepatocellular Carcinoma

    Jul 1, 2025, 00:00

  • HPR142 The Evolution of Value-Based Agreements in US Healthcare: Barriers, Opportunities, and Future Prospects

    Jul 1, 2025, 00:00

  • HTA44 Reimbursement Outcomes for EMA Conditionally Authorized Orphan Drugs (2022-2023): Implications for Joint Clinical Assessment Requirements

    Jul 1, 2025, 00:00

  • RWD111 Unmet Need in CIDP Patients Treated With Immunoglobin: Results of a Multinational Real-World Survey

    Jul 1, 2025, 00:00

  • P57 Frequency of ICER Miscalculation and Misinterpretation in Published Cost-Effectiveness Analysis Comparing More Than Two Alternatives

    Jul 1, 2025, 00:00

  • MSR90 From Bias to Confiden Exploring Quantitative Bias Analysis’ (QBA’s) Role in Matching Adjusted Indirect Treatment Comparison

    Jul 1, 2025, 00:00

  • RWD101 Epidemiology, Demography and Comorbidities of Patients With Osteoporosis at Very High Risk of Fracture in China

    Jul 1, 2025, 00:00

  • P52 A Policy Framework for Multi-Indication Evidence Synthesis in Oncology Health Technology Assessment (HTA)

    Jul 1, 2025, 00:00

  • PCR23 A Growing Trend: The Expanding Use of Patient-reported Outcome Measures (PROMs) in Clinical Trials (2008-2023)

    Jul 1, 2025, 00:00

  • CO37 A Clinical Prediction Model of Asymptomatic Left Ventricular Dysfunction in Survivors of Childhood Cancer in Ontario, Canada

    Jul 1, 2025, 00:00

  • HSD110 Real-World Subcutaneous Monoclonal Antibody Use Trends for Oncology in the US

    Jul 1, 2025, 00:00

  • CO11 Comparative Analysis of Robotic-Assisted, Laparoscopic, and Open Radical Nephrectomy: Trends, Costs, and Clinical Outcomes

    Jul 1, 2025, 00:00

  • EPH62 Estimation of Treatment Eligible Patients With Transthyretin Cardiac Amyloidosis Within a Health Plan

    Jul 1, 2025, 00:00

  • EE224 Evaluating Attributes of Non-Oncology Orphan Approvals From 2015-2024

    Jul 1, 2025, 00:00

  • RWD13 Real-World Use of Biologics in the Treatment of Psoriasis and Ankylosing Spondylitis in China: The Case of Secukinumab

    Jul 1, 2025, 00:00

  • PCR94 Use of Diaries to Capture Patient-Reported Outcomes in FDA New Drug Approvals (2019-2023)

    Jul 1, 2025, 00:00

  • HPR90 Value Communications With US Payers: The Value of Storytelling

    Jul 1, 2025, 00:00

  • PCR107 Differential Item Functioning With the National Eye Institute Visual Function Questionnaire-25 in Patients With Vitreomacular Traction

    Jul 1, 2025, 00:00

  • MT28 Harnessing Digital Measures of Physical Function in Neurological Conditions: Findings From a Targeted Literature Review

    Jul 1, 2025, 00:00

  • MSR116 Trends in Current Smoker Profiles Among US Adults From 2019-2024: An Unsupervised Clustering Analysis

    Jul 1, 2025, 00:00

  • Editorial Board

    Jun 3, 2025, 09:22

  • Costs and Health Outcomes in Economic Evaluations of Person-Centered Care: A Systematic Review

    Jun 1, 2025, 00:00

  • Use of Real-World Evidence in Health Technology Reassessments Across 6 Health Technology Assessment Agencies

    Jun 1, 2025, 00:00

  • Economic Evaluation of Internet-Based Psychological Interventions: A Scoping Review of Methodological Choices

    Jun 1, 2025, 00:00

  • Understanding the Economic Value of Interventions Addressing Perinatal Mental Health Problems: A Literature Review and Methodological Considerations

    Jun 1, 2025, 00:00

  • Quantifying Low-Value Care in Germany: An Observational Study Using Statutory Health Insurance Data From 2018 to 2021

    Jun 1, 2025, 00:00

  • The New Dutch Guideline for Economic Evaluations in Healthcare: Taking the Societal Perspective to the Next Level

    Jun 1, 2025, 00:00

  • Why Is Distributional Cost-Effectiveness Analysis Not Ready for Prime Time in Health Technology Assessment?

    Jun 1, 2025, 00:00

  • US Drug Pricing Patterns Before Loss of Exclusivity

    Jun 1, 2025, 00:00

  • When Do Value-Based Contracts Add Value? Insights From Probabilistic Simulations

    Jun 1, 2025, 00:00

  • The Value of Positron Emission Tomography for Confirmation of Alzheimer’s Disease in the Era of Amyloid-Targeting Therapies

    Jun 1, 2025, 00:00

  • Mapping the Landscape of Open Source Health Economic Models: A Systematic Database Review and Analysis: An ISPOR Special Interest Group Report

    Jun 1, 2025, 00:00

  • Table of Contents

    Jun 1, 2025, 00:00

  • Quality-Adjusted Life Expectancy by Socioeconomic Disadvantage and Remoteness Area: Population Norms for Australia

    Jun 1, 2025, 00:00

  • A Person-Centered eHealth Intervention for Patients With Common Mental Disorders: Cost-Effectiveness Analysis Within a Randomized Controlled Trial

    Jun 1, 2025, 00:00

  • A Factual Inaccuracy Noted in the Conclusions Specifically Regarding the Novelty of the Author’s Work in the Middle East

    Jun 1, 2025, 00:00

  • Performance of the EQ-5D-5L With Skin Irritation and Self-Confidence Bolt-On Items in Patients With Urticaria

    Jun 1, 2025, 00:00

  • Can Adolescents Value the EQ-5D-Y-5L and EQ-5D-5L, and How Do the Values Compare? A Feasibility Study

    Jun 1, 2025, 00:00

  • Drop the “M”: Minimally Important Difference and Change Are Not Independent Properties of an Instrument and Cannot Be Determined as a Single Value Using Statistical Methods

    Jun 1, 2025, 00:00

  • The Health Inequality Impact of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer in the United States: A Distributional Cost-Effectiveness Analysis

    Jun 1, 2025, 00:00

  • Screening for Type 2 Diabetes Mellitus: A Systematic Review of Recent Economic Evaluations

    Jun 1, 2025, 00:00

  • A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland

    Jun 1, 2025, 00:00

  • Editorial Board

    May 7, 2025, 15:10

  • Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare Diseases

    May 1, 2025, 00:00

  • Are Updated COVID-19 Vaccines Still Relevant for All Adult Age Groups? An Economic Evaluation of the Monovalent XBB.1.5 Vaccine in Australia

    May 1, 2025, 00:00

  • Do Machine Learning Approaches Perform Better Than Regression Models in Mapping Studies? A Systematic Review

    May 1, 2025, 00:00

  • A Comparison of International Modeling Methods for Evaluating Health Economics of Colorectal Cancer Screening: A Systematic Review

    May 1, 2025, 00:00

  • How Well Are Women Represented in Authorship in HEOR? An Analysis of Value in Health: An ISPOR Report

    May 1, 2025, 00:00

  • Early Cost-Effectiveness Analysis of Using Whole-Genome Sequencing for Patients With Castration-Resistant Prostate Cancer

    May 1, 2025, 00:00

  • Development and Testing of the Psychometric Properties of 20 Bolt-On Items for the EQ-5D-5L Across 31 Rare Diseases

    May 1, 2025, 00:00

  • Table of Contents

    May 1, 2025, 00:00

  • Public Health Supports Whole Health

    May 1, 2025, 00:00

  • What Does "Whole Health" Really Mean for Health Economics and Outcomes Research?

    May 1, 2025, 00:00

  • Whole Health: A Global Perspective

    May 1, 2025, 00:00

  • Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions: An ISPOR Report

    May 1, 2025, 00:00

  • Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis

    May 1, 2025, 00:00

  • An Acquired Taste: Latent Class Analysis to Compare Adolescent and Adult Preferences for EQ-5D-Y-3L Health States

    May 1, 2025, 00:00

  • The Price Effects of Biosimilars in the United States

    May 1, 2025, 00:00

  • Rare Disease Policy in High-Income Countries: An Overview of Achievements, Challenges, and Solutions

    May 1, 2025, 00:00

  • Managing Uncomplicated Singleton Breech Pregnancy Using the OptiBreech Collaborative Care Pathway: Early Economic Model and Value of Information Analysis

    May 1, 2025, 00:00

  • Capturing the Additional Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists Beyond the Control of Traditional Risk Factors in People With Diabetes

    May 1, 2025, 00:00

  • Taking Health Economics and Outcomes Research Forward: Expanding the Definition of Value to Include Whole Health

    May 1, 2025, 00:00

  • Twenty-Four Years After the Launch of the EU Orphan Regulation: Analyzing Dutch Price Dynamics, Biosimilars, and Generics for Orphan Medicinal Products

    May 1, 2025, 00:00

  • IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer’s Disease

    Apr 1, 2025, 00:00

  • Exploring a Patient-Centered Methodology to Identify Suitable Proxy Conditions as a Source for Utility Data, Using Alopecia Areata as a Case Example

    Apr 1, 2025, 00:00

  • Role of Health Equity in Health Technology Assessment Processes: A Landscape Analysis of 13 Health Systems in Asia

    Apr 1, 2025, 00:00

  • Cost-Effectiveness of a Digitally Supported Care Management Program for Caregivers of People With Dementia

    Apr 1, 2025, 00:00

  • The Application of Time-Driven Activity-Based Costing in Oncology: A Systematic Review

    Apr 1, 2025, 00:00

  • The Health Economics of Alzheimer’s Disease and Related Dementias

    Apr 1, 2025, 00:00

  • A United Kingdom Value Set for the Weight-Specific Adolescent Instrument for Economic Evaluation

    Apr 1, 2025, 00:00

  • How Do Individuals Value Worse-Than-Dead EQ-5D-5L Health States in Composite Time Trade-Off Tasks? A Qualitative Study

    Apr 1, 2025, 00:00

  • A Value Set for EQ-5D-5L in the United Arab Emirates

    Apr 1, 2025, 00:00

  • How Do Bundled Payment Initiatives Account for Differences in Patient Risk Profiles? A Systematic Review

    Apr 1, 2025, 00:00

  • Indirect Costs of Alzheimer’s Disease: Unpaid Caregiver Burden and Patient Productivity Loss

    Apr 1, 2025, 00:00

  • New IPECAD Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer’s Disease Treatment: Development and Use Cases

    Apr 1, 2025, 00:00

  • Using Outcome Information During Consultation Yields Better Shared Decision Making, Better Patient Experiences, and More Positive Expectations: A Comparative Effectiveness Study

    Apr 1, 2025, 00:00

  • A Comparison of the Performance of 6 Surrogacy Models, Including Weighted Linear Regression, Meta-Regression, and Bivariate Meta-Analysis

    Apr 1, 2025, 00:00

  • Reviewer Acknowledgment

    Apr 1, 2025, 00:00

  • Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study

    Apr 1, 2025, 00:00

  • Table of Contents

    Apr 1, 2025, 00:00

  • Age and Gender Differences in the Relationship Between Chronic Pain and Dementia Among Older Australians

    Apr 1, 2025, 00:00

  • A New Approach for Assessing the Value of Informal Care in Alzheimer’s Disease

    Apr 1, 2025, 00:00

  • The Excess Direct Social Costs of Dementia-Related Neuropsychiatric Symptoms: A Regionwide Cohort Study Beyond Silos

    Apr 1, 2025, 00:00

  • Editorial Board

    Mar 26, 2025, 10:50

  • The Impact of Chronic Conditions on Productivity-Adjusted Life-Years in Both the Workplace and Household Settings in the General Adult Population in Finland

    Mar 1, 2025, 00:00

  • Maternal Mental Health Spillovers From Child Illness and Disability: A Dynamic Panel Analysis

    Mar 1, 2025, 00:00

  • Economic Considerations in Designs and Modifications of Multiarm, Multistage Adaptive and Adaptive Platform Randomized Controlled Trials: A Systematic Literature Review

    Mar 1, 2025, 00:00

  • Social Return on Investment Analysis: A Mixed Methods Approach to Assessing the Value of Adult Hospice Services

    Mar 1, 2025, 00:00

  • Prevalence of Immature Survival Data for Anticancer Drugs Presented to the National Institute for Health and Care Excellence Between 2018 and 2022

    Mar 1, 2025, 00:00

  • The Psychometric Properties of the EQ-HWB and EQ-HWB-S in Patients With Breast Cancer: A Comparative Analysis With EQ-5D-5L, FACT-8D, and SWEMWBS

    Mar 1, 2025, 00:00

  • The Estimation of Health State Utility Values for Psychological Distress in Australia: Implications for Future Economic Evaluations

    Mar 1, 2025, 00:00

  • Evaluating the Health and Economic Impacts of Return-to-Work Interventions: A Modeling Study

    Mar 1, 2025, 00:00

  • Estimating the Lifetime Costs and Benefits of the Incredible Years Teacher Classroom Management Intervention Using Data From 30 Months Follow-Up of the Supporting Teachers and childRen in Schools Trial

    Mar 1, 2025, 00:00

  • Estimating the Economic Impacts for Caregivers of Young People With Mental Health Problems in a Brazilian Cohort

    Mar 1, 2025, 00:00

  • The Feasibility of Personalized Endpoints in Assessing Treatment Outcomes for Rare Diseases: A Pilot Study of Goal Attainment Scaling in SCN2A-Associated Developmental Epileptic Encephalopathy

    Mar 1, 2025, 00:00

  • Cost-Utility Analysis of Antipsychotic Reduction and Discontinuation in Patients With Long-Term Schizophrenia and Psychosis in English Mental Health Trusts: The RADAR Study

    Mar 1, 2025, 00:00

  • Table of Contents

    Mar 1, 2025, 00:00

  • Does Regulatory and Reimbursement Parallel Processing Provide Swifter Funded Access to Medicines for Patients? Evaluation of Cancer Medicines Using the Australian Parallel Process

    Mar 1, 2025, 00:00

  • Patient-Informed Value Elements in Cost-Effectiveness Analyses of Major Depressive Disorder Treatment: A Literature Review and Synthesis

    Mar 1, 2025, 00:00

  • Advancing Mental Health Economics: Insights From the Themed Section

    Mar 1, 2025, 00:00

  • Developing an Australian Value Set for the Recovering Quality of Life-Utility Index Instrument Using Discrete Choice Experiment With Duration

    Mar 1, 2025, 00:00

  • A Systematic Literature Review of Important and Meaningful Differences in the EQ-5D Index and Visual Analog Scale Scores

    Mar 1, 2025, 00:00

  • Economic Evaluation of 9 Intersectoral Strategies to Improve Youth Mental Health and Alleviate Financial Burden in Colombia Using System Dynamics Modeling

    Mar 1, 2025, 00:00

  • Editorial Board

    Feb 26, 2025, 12:14

  • The Influence of Recall and Timing of Assessment on the Estimation of Quality-Adjusted Life-Years When Health Fluctuates Recurrently

    Feb 1, 2025, 00:00

  • Generative Artificial Intelligence for Health Technology Assessment: Opportunities, Challenges, and Policy Considerations: An ISPOR Working Group Report

    Feb 1, 2025, 00:00

  • Financial Impacts of Paying for Gene Therapy for Sickle Cell Disease Under Alternative Pricing and Financing Mechanisms

    Feb 1, 2025, 00:00

  • Potential Biases in Post-Stroke Health Utility Estimates by Modified Rankin Scale Scores

    Feb 1, 2025, 00:00

  • A Standardized Measurement and Valuation Scale of Genomic Utility for Policy Decisions: The GUV Scale

    Feb 1, 2025, 00:00

  • Modeling the Potential Health, Health Economic, and Health Inequality Impact of a Large-Scale Rollout of the Drink Less App in England

    Feb 1, 2025, 00:00

  • An Application of the Checklist for Health Economic Quality Evaluations in a Systematic Review Setting

    Feb 1, 2025, 00:00

  • Economic Evaluations of Interventions Addressing Inequalities in Cancer Care: A Systematic Review

    Feb 1, 2025, 00:00

  • Exploring Social Preferences for Health and Well-Being Across the Digital Divide: A Qualitative Investigation Based on Tasks Taken From an Online Discrete Choice Experiment

    Feb 1, 2025, 00:00

  • Prescription Medication Use and Expenditure for Atrial Fibrillation in the United States

    Feb 1, 2025, 00:00

  • Table of Contents

    Feb 1, 2025, 00:00

  • Reporting Uncertainty Around Health-State Values: A Standard Method and Worked Example

    Feb 1, 2025, 00:00

  • Author Reply

    Feb 1, 2025, 00:00

  • Slipping Away: Slippage in Hazard Ratios Over Datacuts and Its Impact on Immuno-oncology Combination Economic Evaluations

    Feb 1, 2025, 00:00

  • The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction

    Feb 1, 2025, 00:00

  • A Systematic Review and Quality Assessment of Cardiovascular Disease–Specific Health-Related Quality-of-Life Instruments: Part II Psychometric Properties

    Feb 1, 2025, 00:00

  • Value Framework Based on Multiple-Criteria Decision Analysis for Assessment of New Health Technologies Under Universal Healthcare Coverage System in Taiwan

    Feb 1, 2025, 00:00

  • Healthcare Costs in the United States by Demographic Characteristics and Comorbidity Status

    Feb 1, 2025, 00:00

  • Measurement Equivalence of Standard and Zoom-Enabled Electronic Clinical Outcome Assessments: Implications for Patient Accessibility in Clinical Trials

    Feb 1, 2025, 00:00

  • Editorial Board

    Jan 31, 2025, 10:40

  • Editorial Board

    Jan 8, 2025, 14:39

  • Value Attribution for Combination Treatments: Two Potential Solutions for an Insoluble Problem

    Jan 1, 2025, 00:00

  • Primer on Health Equity Research in Health Economics and Outcomes Research: An ISPOR Special Interest Group Report

    Jan 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4 (current)
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »